Novo Nordisk A/Sand Eli Lilly and Company reported their third-quarter results on the same day, bringing broad satisfaction to their investors. Meanwhile, imitators and potential successors have been lining up for some time.
Stock Watch: Where Novo And Lilly Lead, Others Follow
AstraZeneca Resurrects Its Metabolic Franchise
AstraZeneca is the latest GLP-1 agonist aspirant after Novo’s and Lilly’s recent earnings season successes. Already, a segmentation of potential patients and frantic competition among new GLP-1 agonists and drug combinations are emerging.
More from Stock Watch
More from Business
• By
On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.
• By
Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.
• By
Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.